Granulocyte-macrophage Colony-stimulating Factor, Interferon and Interleukin-2 as Adjuvant Treatment for Renal Cancer
Status:
Completed
Trial end date:
2010-05-01
Target enrollment:
Participant gender:
Summary
This prospective study assesses toxicity and potential efficacy of granulocyte-macrophage
colony-stimulating factor (GM-CSF), interferon (IFN) alpha and interleukin-2 (IL-2)
postoperatively in patients with high-risk renal cell carcinoma (RCC).